Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Deferasirox alone vs combined deferasirox and deferiprone Responder analysis · people with transfusion‐dependent thalassaemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Deferasirox alone vs combined deferasirox and deferiprone Serum ferritin (ng/mL) · people with transfusion‐dependent thalassaemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Deferasirox alone vs combined deferasirox and deferiprone LIC (mg Fe/g dry weight) · people with transfusion‐dependent thalassaemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Deferasirox alone vs combined deferasirox and deferiprone Satisfaction with treatment · people with transfusion‐dependent thalassaemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Deferasirox vs deferoxamine Responder analysis II (responder: LIC 1 to less than 7 mg Fe/g dw) · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | RR 0.8 [0.69, 0.92] | 1 study · 553 participants | Moderate |
Deferasirox alone vs combined deferasirox and deferiprone Adherence · people with transfusion‐dependent thalassaemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Deferasirox alone vs combined deferasirox and deferiprone AE: serum creatinine increase · people with transfusion‐dependent thalassaemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Combined deferasirox and deferiprone vs deferiprone alone Mortality at any time point · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Combined deferasirox and deferiprone vs deferiprone alone Responder analysis · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Combined deferasirox and deferiprone vs deferiprone alone Serum ferritin (ng/mL) · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Combined deferasirox and deferiprone vs deferiprone alone LIC (mg Fe/g dry weight) · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Combined deferasirox and deferiprone vs deferiprone alone Satisfaction with treatment · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Combined deferasirox and deferiprone vs deferiprone alone Adherence · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Combined deferasirox and deferiprone vs deferiprone alone AE: Serum creatinine increase · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Deferasirox and deferoxamine vs deferoxamine Mortality at any time point · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 94 participants | Low |
Deferasirox vs deferoxamine Serum ferritin (ng/mL): mean change from baseline and at end of study · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 6 studies · 1002 participants | Moderate |
Deferasirox and deferoxamine vs deferoxamine Responder analysis · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferoxamine vs deferoxamine Serum ferritin (ng/mL) ‐ mean at end of study · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 94 participants | Very low |
Deferasirox and deferoxamine vs deferoxamine LIC · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferoxamine vs deferoxamine Satisfaction with treatment · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferoxamine vs deferoxamine Adherence: Discontinuations · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 94 participants | Very low |
Deferasirox and deferoxamine vs deferoxamine AE: serum creatinine increased · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferiprone vs deferiprone and deferoxamine Mortality at any time point · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 96 participants | Low |
Deferasirox and deferiprone vs deferiprone and deferoxamine Responder analysis · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferiprone vs deferiprone and deferoxamine Serum ferritin (ng/mL): mean change from baseline · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 96 participants | Very low |
Deferasirox and deferiprone vs deferiprone and deferoxamine LIC evaluated by MRI R2*: mean change from baseline · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 96 participants | Low |
Deferasirox vs deferoxamine LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 541 participants | Moderate |
Deferasirox and deferiprone vs deferiprone and deferoxamine Satisfaction · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox and deferiprone vs deferiprone and deferoxamine Adherence: Discontinuations · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 96 participants | Very low |
Deferasirox and deferiprone vs deferiprone and deferoxamine Drug‐related AE: serum creatinine increased (≥ 33%) above baseline in 2 consecutive occasions · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | RR 3 [0.32, 27.83] | 1 study · 96 participants | Very low |
Deferasirox vs placebo Mortality at any time point · people with non‐transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 148 participants | Moderate |
Deferasirox vs placebo Responder analysis · people with non‐transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox vs placebo Serum ferritin (ng/mL): mean change from baseline · people with non‐transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 154 participants | Moderate |
Deferasirox vs placebo LIC (mg Fe/g dry weight) evaluated by MRI R2: least squares mean change from baseline · people with non‐transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 1 study · 159 participants | Moderate |
Deferasirox vs placebo Satisfaction with treatment · people with non‐transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Deferasirox vs placebo Adherence: Discontinuations · people with non‐transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | RR 1.32 [0.5, 3.52] | 1 study · 166 participants | Low |
Deferasirox vs placebo AE: abnormal serum creatinine (post‐baseline) · people with non‐transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | RR 3.59 [0.19, 68.4] | 1 study · 166 participants | Very low |
Deferasirox vs deferoxamine Satisfaction with treatment (very satisfied or satisfied): participants previously treated with DFO · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | RR 2.2 [1.89, 2.57] | 1 study · 571 participants | Moderate |
Deferasirox vs deferoxamine Adherence: discontinuations · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | RR 0.95 [0.6, 1.5] | 8 studies · 1211 participants | Low |
Deferasirox vs deferoxamine AE: investigations ‐ isolated serum creatinine increase above ULN · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | RR 2.57 [1.88, 3.51] | 2 studies · 657 participants | Low |
Deferasirox vs deferiprone Mortality at any time point · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | 3 studies · 146 participants | Very low |
Deferasirox vs deferiprone Responder analysis · people with transfusion‐dependent thalassemia Deferasirox for managing iron overload in people with thalassaemia (2017) · Cochrane | no estimate extracted | NR | No studies |
Prophylaxis therapy vs on‐demand therapy with FEIBA Overall bleeding rates: total number of bleeding events · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | 1 study · 26 participants | Low |
High‐dose vs low‐dose rFVIIa AJBR · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs low‐dose rFVIIa Quality of life · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs low‐dose rFVIIa Safety of bypassing agents · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | 2 studies · 46 participants | Moderate |
Prophylaxis therapy vs on‐demand therapy with FEIBA Annualised bleeding rate · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | 1 study · 34 participants | Moderate |
Prophylaxis therapy vs on‐demand therapy with FEIBA Target joint bleeding rate: number of hemarthrosis · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | 1 study · 26 participants | Low |
Prophylaxis therapy vs on‐demand therapy with FEIBA AJBR · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | 1 study · 34 participants | Moderate |
Prophylaxis therapy vs on‐demand therapy with FEIBA Quality of life · adults and children with hemophilia A or B with inhibitors Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (2017) · Cochrane | no estimate extracted | 2 studies · 58 participants | Low |